Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: A multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG

Cindy Franklin*, Peter Mohr, Leonie Bluhm, Friedegund Meier, Marlene Garzarolli, Michael Weichenthal, Katharina Kähler, Imke Grimmelmann, Ralf Gutzmer, Jochen Utikal, Patrick Terheyden, Rudolf Herbst, Sebastian Haferkamp, Claudia Pfoehler, Andrea Forschner, Ulrike Leiter, Fabian Ziller, Frank Meiss, Jens Ulrich, Alexander KreuterChristoffer Gebhardt, Julia Welzel, Bastian Schilling, Martin Kaatz, Karin Scharfetter-Kochanek, Edgar Dippel, Dorothee Nashan, Michael Sachse, Carsten Weishaupt, Harald Löffler, Thilo Gambichler, Carmen Loquai, Lucie Heinzerling, Stephan Grabbe, Dirk Debus, Gaston Schley, Jessica C. Hassel, Gerhard Weyandt, Maike Trommer, Georg Lodde, Jan Malte Placke, Lisa Zimmer, Elisabeth Livingstone, Jürgen Christian Becker, Susanne Horn, Dirk Schadendorf, Selma Ugurel

*Corresponding author for this work
1 Citation (Scopus)


Background Despite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival outcomes dependent on the type of first-line therapy. Methods Patients with metastatic, non-resectable melanoma (AJCCv8 stage IIIC-V) without brain metastasis at start of first-line therapy (1L-therapy) were identified from the prospective multicenter real-world skin cancer registry ADOREG. Study endpoints were incidence of brain metastasis, brain metastasis-free survival (BMFS), progression-free survival (PFS), and overall survival (OS). Results Of 1704 patients, 916 were BRAF wild-type (BRAFwt) and 788 were BRAF V600 mutant (BRAFmut). Median follow-up time after start of 1L-therapy was 40.4 months. BRAFwt patients received 1L-therapy with immune checkpoint inhibitors (ICI) against CTLA-4+PD-1 (n=281) or PD-1 (n=544). In BRAFmut patients, 1L-therapy was ICI in 415 patients (CTLA-4+PD-1, n=108; PD-1, n=264), and BRAF+MEK targeted therapy (TT) in 373 patients. After 24 months, 1L-therapy with BRAF+MEK resulted in a higher incidence of brain metastasis compared with PD-1±CTLA-4 (BRAF+MEK, 30.3%; CTLA-4+PD-1, 22.2%; PD-1, 14.0%). In multivariate analysis, BRAFmut patients developed brain metastases earlier on 1L-therapy with BRAF+MEK than with PD-1±CTLA-4 (CTLA-4+PD-1: HR 0.560, 95% CI 0.332 to 0.945, p=0.030; PD-1: HR 0.575, 95% CI 0.372 to 0.888, p=0.013). Type of 1L-therapy, tumor stage, and age were independent prognostic factors for BMFS in BRAFmut patients. In BRAFwt patients, tumor stage was independently associated with longer BMFS; ECOG Performance status (ECOG-PS), lactate dehydrogenase (LDH), and tumor stage with OS. CTLA-4+PD-1 did not result in better BMFS, PFS, or OS than PD-1 in BRAFwt patients. For BRAFmut patients, multivariate Cox regression revealed ECOG-PS, type of 1L-therapy, tumor stage, and LDH as independent prognostic factors for PFS and OS. 1L-therapy with CTLA-4+PD-1 led to longer OS than PD-1 (HR 1.97, 95% CI 1.122 to 3.455, p=0.018) or BRAF+MEK (HR 2.41, 95% CI 1.432 to 4.054, p=0.001), without PD-1 being superior to BRAF+MEK. Conclusions In BRAFmut patients 1L-therapy with PD-1±CTLA-4 ICI resulted in a delayed and less frequent development of brain metastasis compared with BRAF+MEK TT. 1L-therapy with CTLA-4+PD-1 showed superior OS compared with PD-1 and BRAF+MEK. In BRAFwt patients, no differences in brain metastasis and survival outcomes were detected for CTLA-4+PD-1 compared with PD-1.

Original languageEnglish
Article numbere005828
JournalJournal for ImmunoTherapy of Cancer
Issue number4
Publication statusPublished - 07.04.2023

Cite this